CUV 0.00% $14.30 clinuvel pharmaceuticals limited

Ann: CLINUVEL Newsletter IV - October 2023, page-3

  1. 772 Posts.
    lightbulb Created with Sketch. 219
    Agree a comparison with MSB and SPL pretty naive and I don’t think they know them as well as some holders (I still have some SPL). I see the opposing view on a buyback but at recent levels well below consensus it wouldn’t hurt. I agree however, as PW says it’s only a temporary measure to support the SP and he prefers to use capital elsewhere (conservatively) and makes the point of increasing Dividends to support s/holders. I wish things would have happened sooner, however, s/holders had more than one opportunity to reap large returns at $40. I think this is where PW thinks at times expectations perhaps were ahead of reality. Certainly when you compare CUV with the likes of SPL and MSB I’m pretty happy with CUV over time. GLTA
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.